Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's fo

Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6%

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the p

JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ

Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript

Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus E

Haemonetics (NYSE:HAE) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 bill

Financial release and supplemental presentation accessible online BOSTON, Aug. 6, 2026 /PRNewswire/

Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both im

BOSTON, Aug. 3, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technolog

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earn

BOSTON, July 28, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global medical technolog

American Capital Management Inc. cut its stake in Haemonetics Corporation (NYSE: HAE) by 10.1% durin

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in t

The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quar

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company

HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pr

On June 25, 2026, Haemonetics Corp (HAE) shares rose 6.5% today, bringing the current price to $77.6

BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelli

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reduction

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 202

BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technolog

BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon,

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the p

Analysts upgraded HAE, VIK, and TXN, and raised price targets. Check out other analysts' views o

B of A Securities analyst Craig Bijou upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and rai

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the price

FISCAL 2027 GUIDANCEThe Company issued its fiscal 2027 GAAP total revenueand organic revenue growth

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.29 per share which beat the analyst consens

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the

Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innova

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the p

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.31 per share which beat the analyst consens

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")),

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential m

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel cl